General Neurology
Metal neurotoxicity
Oct. 23, 2023
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
Astrocyte-mediated neuroinflammation and neuroprotective mechanisms in the pathogenesis of Parkinson disease. On exposure to inflammatory stimuli, astrocytes become activated A1 phenotype. A1 phenotype astrocytes secrete pro-inflammatory factors, such as interleukin 1 beta (IL-1b), tumor necrosis factor-alpha (TNF-a), and other inflammatory factors, which further induce neuroinflammation and neurotoxicity mechanisms in the human brain, damaging dopaminergic neurons. A1 phenotype astrocytes secrete pro-inflammatory factors, such as IL-1b, TNF-a, and other inflammatory factors. On the other hand, the neuroprotective mechanism of activated A2 phenotype astrocytes against Parkinson disease includes the release of anti-inflammatory cytokines into the brain as well as the upregulation of neuroprotective trophic factors, anti-inflammatory cytokines including transforming growth factor beta (TGF-β), which inhibit persistent neuroinflammation and, thus, protect dopaminergic neurons. Disease occurs when this balance in the organism is disrupted. (Source: Zhang J, Luo L, Long E, Chen L. Neurotoxicity induced by taxane-derived drugs: analysis of the FAERS database 2017-2021. Expert Opin Drug Saf 2023;22[8]:715-24. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0.)